

# Current Topics in Behavioral Neurosciences

Series Editors:

Mark Geyer, La Jolla, CA, USA

Bart Ellenbroek, Wellington, New Zealand

Charles Marsden, Nottingham, UK

About this series

*Current Topics in Behavioral Neurosciences* provides critical and comprehensive discussions of the most significant areas of behavioral neuroscience research, written by leading international authorities. Each volume offers an informative and contemporary account of its subject, making it an unrivalled reference source. Titles in this series are available in both print and electronic formats.

With the development of new methodologies for brain imaging, genetic and genomic analyses, molecular engineering of mutant animals, novel routes for drug delivery, and sophisticated cross-species behavioral assessments, it is now possible to study behavior relevant to psychiatric and neurological diseases and disorders on the physiological level. The *Behavioral Neurosciences* series focuses on “translational medicine” and cutting-edge technologies. Preclinical and clinical trials for the development of new diagnostics and therapeutics as well as prevention efforts are covered whenever possible.



Jim J. Hagan  
Editor

# Molecular and Functional Models in Neuropsychiatry

 Springer

*Editor*

Dr. Jim J. Hagan  
Global Medical Excellence Cluster (GMEC)  
King's College London  
Guy's Campus, 1.6 Hodgkin Bldg.  
United Kingdom  
james.hagan@kcl.ac.uk

ISSN 1866-3370                      e-ISSN 1866-3389  
ISBN 978-3-642-19702-4          e-ISBN 978-3-642-19703-1  
DOI 10.1007/978-3-642-19703-1  
Springer Heidelberg Dordrecht London New York

Library of Congress Control Number: 2011924781

© Springer-Verlag Berlin Heidelberg 2011

This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilm or in any other way, and storage in data banks. Duplication of this publication or parts thereof is permitted only under the provisions of the German Copyright Law of September 9, 1965, in its current version, and permission for use must always be obtained from Springer. Violations are liable to prosecution under the German Copyright Law.

The use of general descriptive names, registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Product liability: The publishers cannot guarantee the accuracy of any information about dosage and application contained in this book. In every individual case the user must check such information by consulting the relevant literature.

*Cover illustration:* Artistic representation of oscillatory synchrony and timing of neurons in networks by Gyorgy Buzsaki

*Cover design:* Deblük, Berlin

Printed on acid-free paper

Springer is part of Springer Science+Business Media ([www.springer.com](http://www.springer.com))

*For Carole, Luke and Kate*



# Preface

Despite decades of research, common neuropsychiatric diseases remain enigmatic and debilitating disorders which are associated with significant human and economic costs. For example, autism and attention-deficit disorder blight the lives of the young, and schizophrenia, with its profound functional impairments, often impacts in early adulthood with devastating lifelong consequences. Major depressive disorder affects 5–9% of women and 2–3% of men and, according to the World Health Organization (WHO), about 4% of the world's population suffers from some form of drug abuse disorder.

The development of more effective treatments for these and other neuropsychiatric disorders requires scientific progress on a broad front. Animal models have a vital role to play in advancing the field. When deployed in conjunction with detailed study of these diseases in man, they bring the power to make controlled experimental interventions, which allow the functional consequences of genetic variations and polymorphisms to be understood in terms of their cellular systems and behavioural effects. Further, they provide a means by which complex cognitive and behavioural phenomena may be dissected and understood. Finally, they provide a bridge to understanding the effects of drugs on the functioning of the central nervous system, thereby improving our understanding of the actions of those drugs in man.

This volume discusses some of the latest and most exciting advances. The selection of topics eschews the conventional approach of organizing material by discipline, focusing instead on more eclectic, multidisciplinary approaches. It reflects a personal perspective of those areas in which exciting and important new developments are taking place. These span the established areas of study, reflecting both technical and theoretical advances, but also encompass emergent areas such as the use of MRI in the study of systems responses, epigenetic regulation and gene/environment interactions, all topics which will surely play an increasing role in the scientific discourse related to neuropsychiatric diseases.

It is over 60 years since Pauling (Pauling et al. 1949) elucidated the notion of molecular medicine in the context of sickle cell anaemia. The coming decades must see the concept firmly embedded in the practice of neuropsychiatric medicine if the

much needed improvements in therapy are to be delivered. The work discussed in this volume shows some of the ways in which this vision is being realized.

I am grateful to the authors, all leaders in their fields, who so willingly devoted their time, energy and expertise to share their research perspectives and produce a volume which I hope will inform and excite students and experts alike.

February 2011

Jim J. Hagan

## **Reference**

Pauling L, Itano HA, Singer SJ, Wells IC (1949) Sickle cell anemia, a molecular disease. *Science* 110(2865):543–548



# Contents

<b>Mouse Mutagenesis and Disease Models for Neuropsychiatric Disorders</b> .....	1
Yoichi Gondo, Takuya Murata, Shigeru Makino, Ryutaro Fukumura, and Yuichi Ishitsuka	
<b>Drosophila as a Model Organism for the Study of Neuropsychiatric Disorders</b> .....	37
Cahir J. O’Kane	
<b>Transgenic Animal Models of Huntington’s Disease</b> .....	61
Shang-Hsun Yang and Anthony W.S. Chan	
<b>Molecular Genetic Models Related to Schizophrenia and Psychotic Illness: Heuristics and Challenges</b> .....	87
Colm M.P. O’Tuathaigh, Lieve Desbonnet, Paula M. Moran, Brian P. Kirby, and John L. Waddington	
<b>Animal Models of Depression: Molecular Perspectives</b> .....	121
Vaishnav Krishnan and Eric J. Nestler	
<b>Animal Models of ADHD</b> .....	149
A. Bari and T.W. Robbins	
<b>Mouse Models of Autism: Testing Hypotheses About Molecular Mechanisms</b> .....	187
Florence I. Roullet and Jacqueline N. Crawley	
<b>Advances in Animal Models of Drug Addiction</b> .....	213
Christian Heidbreder	

**When the Serotonin Transporter Gene Meets Adversity:  
The Contribution of Animal Models to Understanding Epigenetic  
Mechanisms in Affective Disorders and Resilience ..... 251**  
Klaus-Peter Lesch

**Animal Models of Epigenetic Regulation in Neuropsychiatric  
Disorders ..... 281**  
Chas Bountra, Udo Oppermann, and Tom D. Heightman

**Functional and Pharmacological MRI in Understanding Brain  
Function at a Systems Level ..... 323**  
Angelo Bifone and Alessandro Gozzi

**The Pig as a Model Animal for Studying Cognition  
and Neurobehavioral Disorders ..... 359**  
Elise T. Gieling, Teun Schuurman, Rebecca E. Nordquist,  
and F. Josef van der Staay

**Index ..... 385**

# Contributors

## **A. Bari**

Department of Experimental Psychology, Behavioural and Clinical Neuroscience Institute, University of Cambridge, Downing Street, Cambridge CB2 3EB, UK, bari\_andrea@hotmail.com

## **Angelo Bifone**

Center for Nanotechnology Innovation, Italian Institute of Technology, IIT@NEST, Piazza San Silvestro, 12, Pisa 56127, Italy, angelo.bifone@iit.it

## **Chas Bountra**

Structural Genomics Consortium, University of Oxford, Oxford OX3 7DQ, UK, chas.bountra@sgc.ox.ac.uk

## **Anthony W.S. Chan**

Division of Neuroscience, Department of Human Genetics, Yerkes National Primate Research Center, Emory University School of Medicine, Rm. 2212 Neuroscience Research Building, 954 Gatewood Road, N.E., Atlanta, GA 30329, USA, awchan@emory.edu

## **Jacqueline N. Crawley**

Laboratory of Behavioral Neuroscience, Intramural Research Program, National Institute of Mental Health, Building 35 Room 1C-903/909, Mail Code 3730, Bethesda, MD 20892-3730, USA, crawleyj@mail.nih.gov

## **Lieve Desbonnet**

Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, 123 St., Stephen's Green, Dublin 2, Ireland

**Ryutaro Fukumura**

Mutagenesis and Genomics Team, RIKEN BioResource Center, 3-1-1 Koyadai, Tsukuba, Ibaraki 305-0074, Japan

**Elise T. Gieling**

Program 'Emotion and Cognition', Department of Farm Animal Health, Veterinary Faculty, Utrecht University, PO Box 80166, Utrecht 3508 TD, Netherlands and Rudolf Magnus Institute of Neuroscience, Universiteitsweg 100, Utrecht 3584 CG, The Netherlands

**Yoichi Gondo**

Mutagenesis and Genomics Team, RIKEN BioResource Center, 3-1-1 Koyadai, Tsukuba, Ibaraki 305-0074, Japan, gondo@brc.riken.jp

**Alessandro Gozzi**

Center for Nanotechnology Innovation, Italian Institute of Technology, IIT@NEST, Piazza San Silvestro, 12, Pisa 56127, Italy

**Christian Heidbreder**

Reckitt Benckiser Pharmaceuticals Inc., 10710 Midlothian Turnpike, Suite 430, Richmond, VA 23235, USA, christian.heidbreder@rb.com

**Tom D. Heightman**

Structural Genomics Consortium, University of Oxford, Oxford OX3 7DQ, UK

**Yuichi Ishitsuka**

Mutagenesis and Genomics Team, RIKEN BioResource Center, 3-1-1 Koyadai, Tsukuba, Ibaraki 305-0074, Japan

**Brian P. Kirby**

School of Pharmacy, Royal College of Surgeons in Ireland, Dublin, Ireland

**Vaishnav Krishnan**

Departments of Internal Medicine, Psychiatry and Neuroscience, The University of Texas Southwestern Medical Center, Dallas, TX, USA, vaishnav.krishnan@alumni.utsouthwestern.edu

**Klaus-Peter Lesch**

Molecular Psychiatry, ADHD Clinical Research Network, Laboratory of Translational Neuroscience, Department of Psychiatry, Psychosomatics and Psychotherapy, University of Wuerzburg, Fuechsleinstr. 15, 97080 Wuerzburg, Germany and Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, European Graduate School for Neuroscience (EURON), Maastricht University, P.O. Box 616, 6200 MD Maastricht, The Netherlands, kplesch@mail.uni-wuerzburg.de

**Shigeru Makino**

Mutagenesis and Genomics Team, RIKEN BioResource Center, 3-1-1 Koyadai, Tsukuba, Ibaraki 305-0074, Japan

**Paula M. Moran**

School of Psychology, University of Nottingham, Nottingham, UK

**Takuya Murata**

Mutagenesis and Genomics Team, RIKEN BioResource Center, 3-1-1 Koyadai, Tsukuba, Ibaraki 305-0074, Japan

**Eric J. Nestler**

Fishberg Department of Neuroscience, Mount Sinai School of Medicine, New York, NY, USA

**Rebecca E. Nordquist**

Program 'Emotion and Cognition', Department of Farm Animal Health, Veterinary Faculty, Utrecht University, PO Box 80166, Utrecht 3508 TD, The Netherlands and Rudolf Magnus Institute of Neuroscience, Universiteitsweg 100, Utrecht 3584 CG, The Netherlands

**Cahir J.O'Kane**

Department of Genetics, University of Cambridge, Downing Street, Cambridge CB2 3EH, UK, c.okane@gen.cam.ac.uk

**Udo Oppermann**

Structural Genomics Consortium, University of Oxford, Oxford OX3 7DQ, UK and Botnar Research Centre, Oxford Biomedical Research Unit, University of Oxford, Oxford OX3 7LD, UK

**Colm M.P.O'Tuathaigh**

Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, 123 St. Stephen's Green, Dublin 2, Ireland, cotuathaigh@rcsi.ie

**T.W. Robbins**

Department of Experimental Psychology, Behavioural and Clinical Neuroscience Institute, University of Cambridge, Downing Street, Cambridge, CB2 3EB, UK, twr2@cam.ac.uk

**Florence I. Roulet**

Laboratory of Behavioral Neuroscience, Intramural Research Program, National Institute of Mental Health, Building 35 Room 1C-903/909, Mail Code 3730 Bethesda, MD 20892-3730, USA, firoulet@gmail.com

**Teun Schuurman**

BioMedical Research, Wageningen University and Research Center, PO Box 65, Lelystad 8200 AB, The Netherlands

**F. Josef van der Staay**

Program 'Emotion and Cognition', Department of Farm Animal Health, Veterinary Faculty, Utrecht University, PO Box 80166, Utrecht 3508 TD, The Netherlands and Rudolf Magnus Institute of Neuroscience, Universiteitsweg 100, Utrecht 3584 CG, The Netherlands

**John L. Waddington**

Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, 123 St. Stephen's Green, Dublin 2, Ireland

**Shang-Hsun Yang**

Department of Physiology, National Cheng Kung University Medical College, 1, University Road, Tainan 70101, Taiwan, syang@mail.ncku.edu.tw